|
- Alectinib - Wikipedia
Alectinib was granted an accelerated approval by the US Food and Drug Administration (FDA) in December 2015, to treat people with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori)
- Alectinib: Uses, Dosage, Side Effects, Warnings - Drugs. com
Alectinib (Alecensa) is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene
- Treatment Option for ALK+ NSCLC
Visit the official patient website for ALECENSA® (alectinib) See full safety for more information
- Alectinib (oral route) - Side effects dosage
Alectinib is used to treat non-small cell lung cancer (NSCLC) that has spread or to help prevent NSCLC from coming back after the tumor has been removed by surgery in patients whose tumors have an abnormal anaplastic lymphoma kinase (ALK) gene
- Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
- Alecensa (alectinib): Uses, Side Effects, Interactions . . . - WebMD
Alecensa (alectinib) is commonly used for treating certain types of non-small cell lung cancer (NSCLC) It is used to prevent NSCLC from coming back after surgery to remove the tumor
- Alectinib: MedlinePlus Drug Information
Alectinib is used to treat a certain type of non-small-cell lung cancer (NSCLC) that has spread to other parts of the body Alectinib is in a class of medications called kinase inhibitors
- Alectinib Targeted Therapy: Lung Cancer Uses, Side Effects
Alectinib is a type of targeted therapy that works by selectively inhibiting the activity of ALK protein and “rearranged during transfection” (RET) protein, which cause lung cancers
|
|
|